Régis Sodoyer
Régis Sodoyer has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amélie De Saint Jean
Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France
1 shared publication - Bettina Werle
BIOASTER, Protein and Expression System Engineering unit, 40 avenue Tony Garnier, 69007 Lyon, France
1 shared publication - Catherine Moste
Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France
1 shared publication - Charlotte Mignon
BIOASTER, Lyon, France
1 shared publication - Houda Boukhebza
Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France
1 shared publication - Isabelle Legastelois
Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France
1 shared publication
Latest Publications
- Open Access
Antibiotic-Free Selection in Biotherapeutics: Now and Forever
The continuously improving sophistication of molecular engineering techniques gives access to novel classes of bio-therapeutics and new challenges for their production in full respect of the strengthening regulations. Among these biologic agents are DNA based vaccines or gene therapy products and to a lesser extent genetically engineered live vaccines or delivery vehicles. The use of antibiotic-based selection, frequently associated with genetic manipulation of microorganism is currently undergoing a profound metamorphosis with the implementation and diversification of alternative selection means. This short review will present examples of alternatives to antibiotic selection and their context of application to highlight their ineluctable invasion of the bio-therapeutic world.
Open AccessAntibiotic-Free Selection in Biotherapeutics: Now and Forever
The continuously improving sophistication of molecular engineering techniques gives access to novel classes of bio-therapeutics and new challenges for their production in full respect of the strengthening regulations. Among these biologic agents are DNA based vaccines or gene therapy products and to a lesser extent genetically engineered live vaccines or delivery vehicles. The use of antibiotic-based selection, frequently associated with genetic manipulation of microorganism is currently undergoing a profound metamorphosis with the implementation and diversification of alternative selection means. This short review will present examples of alternatives to antibiotic selection and their context of application to highlight their ineluctable invasion of the bio-therapeutic world.